Literature DB >> 23298620

Characterization of a Norwegian cherubism cohort; molecular genetic findings, oral manifestations and quality of life.

Trine Prescott1, Maria Redfors, Cecilie Fremstad Rustad, Kristin Louise Eiklid, Amy Østertun Geirdal, Kari Storhaug, Janicke Liaaen Jensen.   

Abstract

Bilateral multilocular radiolucencies of the mandible are the main feature of cherubism (OMIM #118400), a rare autosomal dominant disorder primarily affecting the jaw. Typically, symmetrical swelling of the lower face is evident from around three years of age and increases until puberty. The underlying radiolucent lesions consist of vascular fibrotic stroma with scattered multinuclear giant cells. By age 30 years the facial contours are often unremarkable. Missing and displaced teeth as well as premature tooth loss are characteristic. Diagnosis rests upon a combination of clinical, radiographic, histological and molecular findings. SH3BP2 is currently the only gene known to be associated with cherubism. This cross-sectional study describes oral manifestations, quality of life and results of mutation analysis of SH3BP2 in 11 females and 13 males ages five to 84 years with cherubism. One individual with molecularly confirmed Noonan syndrome was excluded from the cohort. Standard statistical tools were used to analyze quality of life data. Mutation analysis was positive in all 22 familial and negative in both sporadic cases. Disease manifestations in mutation carriers varied from none to severe. Although intra-familial variability was marked, we found no evidence of non-penetrance, and females were on average more severely affected than males. Dental sequelae were pronounced; adults lacked a mean of 13 teeth (range 2-28), 13 of 17 individuals aged 16 years and older had removable or fixed dentures and five had dental implants; implant survival rate was 79%. In spite of pronounced disease manifestations and dental sequelae, adult quality of life was good.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23298620     DOI: 10.1016/j.ejmg.2012.12.008

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

1.  Cherubism.

Authors:  Nurgül Kömerik; Betül Taş; Levent Önal
Journal:  Head Neck Pathol       Date:  2013-09-14

2.  Cherubism: panoramic and CT features in adults.

Authors:  M Redfors; J L Jensen; K Storhaug; T Prescott; T A Larheim
Journal:  Dentomaxillofac Radiol       Date:  2013-09-18       Impact factor: 2.419

3.  Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.

Authors:  Teruhito Yoshitaka; Mizuho Kittaka; Shu Ishida; Noriyoshi Mizuno; Tomoyuki Mukai; Yasuyoshi Ueki
Journal:  Bone       Date:  2014-10-31       Impact factor: 4.398

4.  Novel ANO5 mutation c.1067G>T (p.C356F) identified by whole genome sequencing in a big family with atypical gnathodiaphyseal dysplasia.

Authors:  Binghui Zeng; Junkun Liao; Hanqing Zhang; Sha Fu; Weixiong Chen; Guokai Pan; Qunxing Li; Weiliang Chen; Soldano Ferrone; Binghao Wu; Sheng Sun; Jiali Hu; Michael Ho-Young Ahn; Zhaoyu Lin; Dongsheng Yu; Zhanpeng Ou; Xinhui Wang; Fengbo Mo; Nasi Huang; James A Hamilton; Jinsong Li; Song Fan
Journal:  Head Neck       Date:  2018-12-15       Impact factor: 3.147

5.  Unusual Characteristics and Variable Expressivity in a Brazilian Family with Cherubism.

Authors:  Desirée Deconte; Elisa Pacheco Estima Correia; Géssica Haubert; Vinicius de Souza; Jamile Dutra Correia; Marcia Angelica Peter Maahs; Paulo Ricardo Gazzola Zen; Marilu Fiegenbaum; Rafael Fabiano Machado Rosa
Journal:  J Pediatr Genet       Date:  2020-02-28

6.  Living with orofacial conditions: psychological distress and quality of life in adults affected with Treacher Collins syndrome, cherubism, or oligodontia/ectodermal dysplasia-a comparative study.

Authors:  Amy Østertun Geirdal; Solfrid Sørgjerd Saltnes; Kari Storhaug; Pamela Åsten; Hilde Nordgarden; Janicke Liaaen Jensen
Journal:  Qual Life Res       Date:  2014-10-25       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.